TCRX vs TECX

TScan Therapeutics, Inc. vs Tectonic Therapeutic, Inc. — Valuation Comparison 2026

TCRX

Biotechnology
TScan Therapeutics, Inc.
Quality
6.4
out of 10
Value Trap
24
SAFE
Price
$1.08
Last close
Models
9/13
Active
VS

TECX

Biotechnology
Tectonic Therapeutic, Inc.
Quality
4.3
out of 10
Value Trap
18
SAFE
Price
$29.78
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType TCRX Fair ValueTCRX Upside TECX Fair ValueTECX Upside
Bayesian DCF Intrinsic $0.71 -34.5% $14.84 -50.2%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $1.66 +53.8% $3.72 -87.4%
Dynamic NAV Asset-Based $2.48 +130.0% $18.11 -39.2%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for TCRX vs TECX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

TCRX vs TECX — Which Stock Is More Undervalued?

TCRX scores higher with a 6.4/10 quality rating vs TECX's 4.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing TScan Therapeutics, Inc. (TCRX) and Tectonic Therapeutic, Inc. (TECX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

TCRX currently trades at $1.08 with a QOC of 6.4/10, while TECX trades at $29.78 with a QOC of 4.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).